Newer Pharmacologic Treatments in Adults With Type 2 Diabetes
Publication Date: April 19, 2024
Last Updated: April 19, 2024
Summary of Recommendations
ACP recommends adding a sodium–glucose cotransporter-2 (SGLT-2) inhibitor or glucagon-like peptide-1 (GLP-1) agonist to metformin and lifestyle modifications in adults with type 2 diabetes and inadequate glycemic control. (S, H )
- Use an SGLT-2 inhibitor to reduce the risk for all-cause mortality, major adverse cardiovascular events, progression of chronic kidney disease, and hospitalization due to congestive heart failure.
- Use a GLP-1 agonist to reduce the risk for all-cause mortality, major adverse cardiovascular events, and stroke.
620
Title
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes
Authoring Organization
American College of Physicians